Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

6
Thailand Wants to Have Its (Hash) Cake and Eat It Too - Bloomberg

3h bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PFZ NVS GSK 500680 PFE GSK PFIZER

8
Is a Surprise in the Cards for Novartis in Q2 Earnings?

17h zacks
Swiss pharma-giant Novartis AG (NVS - Free Report) is scheduled to report second-quarter 2018 results on Jul 18.
AMGN POOL GTT NVS GSK GSK ONCE

25
Your Daily Pharma Scoop: Zogenix Zooms, Zynerba's Changing Fortunes, AbbVie Proceeds

2018-07-15 seekingalpha
Discussion: Zogenix (ZGNX) announced positive result of a second Phase 3 clinical trial of its ZX008 (low-dose fenfluramine hydrochloride) in Dravet syndrome. The disease is a rare and severe form of epilepsy in children and young adults. Patients in the group under trial experienced a significant betterment, of 54.7% (compared to placebo) decrease in mean monthly convulsive seizures. Both the key secondary endpoints were also met by the trial results.
SGEN AST.WS XLRN AST XNCR CELG GSK ABBV ZYNE ZGNX GSK ABBV

29
Superbugs Win Another Round as Big Pharma Leaves Antibiotics - Bloomberg

2018-07-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
AZN PRTK MDCO MTFB MLNT ACT GSK RHHBF MTFBF RHHVF AGN AGN.PRA RHHBY NVS GSK AKAO

5
Merck's Keytruda Gets FDA's Priority Review for Liver Cancer

2018-07-12 zacks
Merck & Co., Inc. (MRK - Free Report) announced that the FDA has granted priority review to a supplemental new drug application (sBLA) for its PD-L1 inhibitor, Keytruda.
MRK AMGN GSK PFE GSK

17
A $6 Billion China Startup Wants to Be the Amazon of Health Care - Bloomberg

2018-07-07 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
0017 SFOSF BABA NWSGY 0659 0700 AAGIY GSK BIDU GSK NWSZF AAIGF

85
Major Biopharma Catalysts on July’s FDA Calendar

2018-07-07 247wallst
Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. The amount of risk involved ranges from fair to great, should a study come back negative or a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be massive upside.
CBIO TBPH NBIX GSK ZYNE ABBV GSK ABBV DRRX PGNX

5
PFE vs. GSK: Which Stock Is the Better Value Option?

2018-07-04 zacks
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE - Free Report) and GlaxoSmithKline (GSK - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
BLT BHP BHPBF BBL GSK BHP BHPLF PFE GSK

4
PRESS DIGEST- British Business - July 4

2018-07-03 reuters
July 4 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
SHI WPPGF RYAOF CIOIF WPPGY GSK RYAAY GSK CIOIY

4
Liquidia Technologies Starts IPO Process

2018-07-03 seekingalpha
The firm is advancing a pipeline of drug treatments using its PRINT dry inhaled technology portfolio.
GSK GSK

17
WeDoctor, a $6 billion China startup, wants to be the Amazon of health care

2018-07-03 livemint
Hong Kong: As soon as you’re diagnosed as diabetic, ads for treatments show up on social feeds. You get alerts on health supplements, maybe nutrition tips. Prompts on insurance policies pop up on your phone.
0017 SFOSF BABA NWSGY 0659 0700 AAGIY GSK BIDU GSK NWSZF AAIGF

46
Novartis to Spin-Off Alcon as Separate Trading Company

2018-07-02 zacks
Novartis AG (NVS - Free Report) announced that it intends to spinoff its ophthalmology division, Alcon, into a separately-traded standalone company in order to grow as a medicines company solely.
WFC WFCNP WFC.WS GILD WFC.PRL WFC.PRJ GSK ONCE WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN NVS GSK WFC.PRY WFC.PRX WFC.PRW WFC.PRV

124
Liquidia To File IPO - What Investors Need To Know

2018-07-02 seekingalpha
Liquidia Technologies (LQDA), has filed the necessary paperwork with the SEC to make an initial public offering. The biopharma company is seeking to raise at least $57 million and will trade on the NASDAQ Capital Market. Jefferies and Cowen will run the book on the IPO.
MNKD ARNA GSK HRTX AERI UTHR INSM ALIOY GSK DRRX

23
New Strong Sell Stocks for July 2nd

2018-07-02 zacks
Axalta Coating Systems Ltd. (AXTA - Free Report) is a manufacturer of high-performance coatings. The Zacks Consensus Estimate for its current year earnings has been revised 0.8% downward over the last 30 days.
MG MDPEB AXTA GSK DXC.WI MDP GSK DXC

65
Sanofi (SNY) Finalizes Deal for European Generic Unit Sale

2018-06-29 zacks
Sanofi (SNY - Free Report) announced that it has finalized its negotiations with private equity firm, Advent International to sell Zentiva, Sanofi’s generic business unit in Europe. The companies have signed a share purchase agreement worth $2.2 billion (1.9 billion euros).
CELGZ CELG NVS GSK PII GSK SNY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

46m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to LSE:GSK / GLAXOSMITHKLINE on message board site Silicon Investor.

After Glaxou0027s genital herpes vaccine flop, check out Agenus SI Pigskin Pick em
FOOTBALL: 1999 Pigskin Prognostication Contest TGSK - Great White Marine u0026 Recreation, Inc.
FOOTBALL: 1998 Pigskin Prognostication Contest